Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy
about
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment responsePrognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerThe relationship between prognostic and predictive factors in the management of breast cancer.BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.The identified needs of ethnic minority groups with cancer within the community: a review of the literature.The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancerNew castanospermine glycoside analogues inhibit breast cancer cell proliferation and induce apoptosis without affecting normal cellsPredictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trialsDifferences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.Neoadjuvant chemotherapy in breast cancer.Genetic factors influencing pyrimidine-antagonist chemotherapy.Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activityImmunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significanceMolecular biology of breast cancer.Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancerPrognostic value of bcl-2 expression among women with breast cancer in Libya.Bcl-2 expression and triple negative profile in breast carcinoma.Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.Interleukin-6 (IL-6) does not change the expression of Bcl-2 protein in the prevention of cisplatin-induced apoptosis in ovarian cancer cell lines.Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene.The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women.Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women.Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy.Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.Bcl-2 antigen expression in luminal A and triple-negative breast cancer.Cell kinetics and apoptosis in laryngeal carcinoma patients.Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
P2860
Q24801874-FD4F440F-8F97-4AAF-94C0-9B8157558958Q33254067-A66CE717-6CB3-4A5D-B8E1-20A97C966CCAQ33281956-3411FF3F-506F-4BB6-845C-2C51D7B5B122Q33304691-E5F83652-1C50-420C-967B-78A68767BA35Q33538455-4FA12604-A645-432B-B9F0-9D2F810432F5Q34491903-914E69C4-E3CC-49F9-B1D7-368492B36B97Q34503843-D753D78F-301B-4608-B0CD-C5513EC69366Q34578129-983044A6-B76C-4B70-BEA7-186F33B04961Q35016962-7D87EA99-1183-4C7E-9F96-3A8F5C5800E6Q35237197-D42BD054-7E62-4147-AB12-CB0EAE2DAE63Q35558130-ED31DB78-A68A-467A-8ACF-7E3DA10AE15CQ35809680-39FD8105-2CD6-4997-A561-F57F5F3E987AQ36001232-3A558D06-A22D-4D10-A3B2-953862002F1EQ36205831-9149989F-D787-477C-841F-C6886B646F75Q36291775-F600A67B-E967-4DDF-BD1D-FB15DD67489EQ36292668-B4A2281D-A574-4259-9A0B-E91938B25F73Q36457054-89E3FCF9-5963-426C-B770-230D9159CECEQ36621098-62094A50-A36D-4641-9816-CBCFA48000BAQ36678716-DF1E4E99-6A95-44AE-82E4-8F26BE78C1FFQ38994709-2882414E-834E-45B9-BAB7-1D0E6E0B80F9Q39116598-DD8BAC2A-CBA8-4D17-A557-8C813B216401Q39918613-57226829-254A-467E-BD9F-99C21458187AQ40969022-0DF26789-C190-4C7B-A2E3-D9F569F34207Q43072014-D6D5F925-DD31-4656-AA38-1024CFEE8641Q44278738-CE8BA193-EF62-4996-893D-BBE5DC51D68DQ45986058-C0DB1B45-760E-47D3-9C6C-2667F8B6DF46Q47138780-9772D047-6E4C-435F-BCA4-E69576DF6D7CQ47336050-BEB5DEFB-0FC2-49EB-B877-D3683C58D23EQ47961905-9B9103EB-BD70-4621-8AC0-DA2F9BBA2B39Q48014540-F6490C71-70A0-43C4-83C3-256FB16E7DCFQ52866295-A7B14A37-B289-40F8-BA18-E4A987C72510
P2860
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Expression of Bcl-2 in node-ne ...... of perioperative chemotherapy
@ast
Expression of Bcl-2 in node-ne ...... of perioperative chemotherapy
@en
type
label
Expression of Bcl-2 in node-ne ...... of perioperative chemotherapy
@ast
Expression of Bcl-2 in node-ne ...... of perioperative chemotherapy
@en
prefLabel
Expression of Bcl-2 in node-ne ...... of perioperative chemotherapy
@ast
Expression of Bcl-2 in node-ne ...... of perioperative chemotherapy
@en
P2093
P2860
P356
P1476
Expression of Bcl-2 in node-ne ...... of perioperative chemotherapy
@en
P2093
Clahsen PC
Delobelle-Deroide A
Mandard AM
van Dierendonck JH
van Slooten HJ
van de Velde CJ
P2860
P2888
P356
10.1038/BJC.1996.319
P407
P577
1996-07-01T00:00:00Z